Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression氯胺酮与电休克治疗用于非精神病性难治性重度抑郁障碍NEW ENGLAND JOURNAL OF MEDICINEIF78.52023-06-2299PRE
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trialNEUROPSYCHOPHARMACOLOGYIF7.12021-11-2719OAAI
Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depressioncontemporary clinical trialsIF1.42019-12-019OAAI
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (vol 25, pg 1592, 2020)MOLECULAR PSYCHIATRYIF10.12019-01-079OA
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)MOLECULAR PSYCHIATRYIF10.12018-10-03266OAAI
Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled TrialNEUROPSYCHOPHARMACOLOGYIF7.12014-11-06113OAAI
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled TrialAMERICAN JOURNAL OF PSYCHIATRYIF14.72013-10-01971OAAI
The Emerging Use of Ketamine for Anesthesia and Sedation in Traumatic Brain InjuriesCNS NEUROSCIENCE & THERAPEUTICSIF52013-03-1165OA
D-Cycloserine administration does not affect neurocognition in concurrent cocaine- and nicotine-dependent volunteersPHARMACOLOGY BIOCHEMISTRY AND BEHAVIORIF2.52012-12-012PRE